|
|
Transgene - Comparative Business Analysis Snapshot
Business Description
Transgene. The Group's principal activity is to discover and develop therapeutic vaccines. The Group develops gene-based vaccines used in treatment of cancer and infectious diseases. The Group follows three different strategies. The Group develops vaccines and partners with pharmaceutical companies for further development. The Group also independently develops and commercializes vaccines for certain special markets. The third strategy is to license vector technologies to companies with proprietary genes for short and medium term revenues. The Group markets the products under the brand names MYoDys, TG 4010, TG 4001, TG 1042 and TG 4040. The Group operates mainly in France.
Competitor Analysis
This analysis compares Transgene with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
|
|
|
|
